Zobrazeno 1 - 10
of 17
pro vyhledávání: '"BUZDAR, A"'
Autor:
Paul E. Goss, James N. Ingle, Hu Li, Aman U. Buzdar, Matthew P. Goetz, Junmei Cairns, Richard M. Weinshilboum, Tanda M. Dudenkov, Erin E. Carlson, Matthew J. Ellis, Krishna R. Kalari, Liewei Wang, Jie Na, Barbara Goodnature, Mark E. Robson, Lois E. Shepherd, Mehrab Ghanat Bari
Publikováno v:
JCI Insight, Vol 5, Iss 16 (2020)
JCI Insight
JCI Insight
Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence. Using a genome-wide association study of patients entered on MA.27, a phase III randomized trial of anastrozole versus exem
Autor:
Clark V. Williard, Liewei Wang, Tracy L. Pietrzak, Matthew P. Goetz, Anthony Batzler, Erin E. Carlson, Yusuke Nakamura, Donald W. Northfelt, Michiaki Kubo, Gregory D. Jenkins, Alvaro Moreno-Aspita, Irada Ibrahim-zada, Krishna R. Kalari, Richard M. Weinshilboum, Aman U. Buzdar, Poulami Barman, Mark E. Robson, Tanda M. Dudenkov, James N. Ingle
Publikováno v:
Breast Cancer Research and Treatment. 164:189-199
Estrone (E1), the major circulating estrogen in postmenopausal women, promotes estrogen-receptor positive (ER+) breast tumor growth and proliferation. Two major reactions contribute to E1 plasma concentrations, aromatase (CYP19A1) catalyzed E1 synthe
Autor:
Shazia Bano, Mustansar Mahmood Waraich, Muhammad Afzal, Saeed Ahmed Buzdar, Tayyaba Zafar, Shahnaz Akhtar
Publikováno v:
Journal of Magnetism and Magnetic Materials. 417:284-290
We report evidence for the promising application of bovine serum albumin (BSA), chitosan (CS) or carboxymethyl cellulose (CMC) coated NiFe 2 O 4 cores for improved biocompatibility and enhanced T2 relaxivity, through a single combinatorial approach.
Autor:
Dowsett, M, Forbes, JF, Bradley, R, Ingle, J, Aihara, T, Bliss, J, Boccardo, F, Coates, A, Coombes, RC, Cuzick, J, Dubsky, P, Gnant, M, Kaufmann, M, Kilburn, L, Perrone, F, Rea, D, Thuerlimann, B, Van de Velde, C, Pan, H, Peto, R, Davies, C, Gray, R, Baum, M, Buzdar, A, Sestak, I, Markopoulos, C, Fesl, C, Jakesz, R, Colleoni, M, Gelber, R, Regan, M, Von Minckwitz, G, Snowdon, C, Goss, P, Pritchard, K, Anderson, S, Costantino, J, Mamounas, E, Ohashi, Y, Watanabe, T, Bastiaannet, E
Publikováno v:
Lancet, 386(10001), 1341-1352. Elsevier Science
Lancet, 386(10001), 1341-1352. Elsevier Limited
2015, ' Aromatase inhibitors versus tamoxifen in early breast cancer : patient-level meta-analysis of the randomised trials ', The Lancet, vol. 386, no. 10001, pp. 1341-52 . https://doi.org/10.1016/S0140-6736(15)61074-1
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) & Clarke, M 2015, ' Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials ', Lancet, vol. 386, no. 10001, pp. 1341–1352 . https://doi.org/10.1016/S0140-6736(15)61074-1
Lancet, 386(10001), 1341-1352
LANCET, 386(10001), 1341-1352. ELSEVIER SCIENCE INC
Lancet, 386(10001), 1341-1352. Elsevier Limited
2015, ' Aromatase inhibitors versus tamoxifen in early breast cancer : patient-level meta-analysis of the randomised trials ', The Lancet, vol. 386, no. 10001, pp. 1341-52 . https://doi.org/10.1016/S0140-6736(15)61074-1
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) & Clarke, M 2015, ' Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials ', Lancet, vol. 386, no. 10001, pp. 1341–1352 . https://doi.org/10.1016/S0140-6736(15)61074-1
Lancet, 386(10001), 1341-1352
LANCET, 386(10001), 1341-1352. ELSEVIER SCIENCE INC
Background The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.Methods We undertook meta-analyses of individual data on 31 920 postmenopausal women with oestrogen-receptor-posit
Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer
Autor:
John F. Forbes, Walter Jonat, Aman U. Buzdar, Jack Cuzick, Rowan T. Chlebowski, Sean Duffy, Peter M. Ravdin
Publikováno v:
Current Medical Research and Opinion. 22:1575-1585
Over the past few years, data have been published concerning the relative efficacy and safety profiles of tamoxifen and the aromatase inhibitors (AIs) in the adjuvant therapy setting for women with early hormone receptor-positive breast cancer. Recen
Autor:
Eleftherios P. Mamounas, Michael Baum, Mitchell Dowsett, Anthony Howell, Generosa Grana, Robert W. Carlson, Richard M. Elledge, William J. Gradishar, D. Craig Allred, Aman U. Buzdar
Publikováno v:
The Breast Journal. 9:213-222
This article summarizes the conclusions of a meeting of diverse breast cancer experts who discussed issues, controversies, and new clinical trial results relevant to the use of aromatase inhibitors for treating postmenopausal women with breast cancer
Autor:
Aman U. Buzdar, Vasily J. Assikis
Publikováno v:
Seminars in Oncology. 29:120-128
Third-generation aromatase inhibitors (anastrozole, letrozole, and exemestane) have emerged as an alternative first-line endocrine treatment for postmenopausal breast cancer patients with hormone-responsive disease. Their clinical efficacy, excellent
Autor:
Aman U. Buzdar
Publikováno v:
Endocrine-related cancer. :219-225
A number of potent and selective non-steroidal aromatase inhibitors are now available for treatment of advanced breast cancer in postmenopausal women, of which anastrozole and letrozole, in particular, represent a significant advantage over the earli
Publikováno v:
Cancer. 79:730-739
BACKGROUND Anastrozole is a new oral aromatase inhibitor with highly potent and selective activity for the aromatase enzyme. In a Phase III trial, the efficacy and tolerability of anastrozole, given in doses of 1 and 10 mg orally once daily, and mege
Autor:
Randy A. Weintraub, Matthew P. Goetz, Clark V. Williard, Daniel J. Schaid, Richard M. Weinshilboum, Anthony Batzler, Janet E. Olson, James N. Ingle, Aman U. Buzdar, Mark E. Robson, Edith A. Perez, Zeruesenay Desta, David A. Flockhart, Donald W. Northfelt
Publikováno v:
Cancer research. 70(8)
Aromatase inhibitors play a prominent role in the management of postmenopausal women with endocrine-sensitive breast cancer, but there is large variability in both efficacy and tolerability. The purpose of our study was to define interindividual vari